Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 29 studies | 35% ± 15% | |
| astrocyte | 20 studies | 40% ± 14% | |
| endothelial cell of lymphatic vessel | 16 studies | 29% ± 9% | |
| pericyte | 15 studies | 35% ± 11% | |
| smooth muscle cell | 14 studies | 29% ± 12% | |
| glutamatergic neuron | 11 studies | 49% ± 20% | |
| myofibroblast cell | 10 studies | 45% ± 21% | |
| connective tissue cell | 9 studies | 37% ± 10% | |
| GABAergic neuron | 9 studies | 44% ± 20% | |
| oligodendrocyte precursor cell | 6 studies | 21% ± 5% | |
| neuron | 6 studies | 37% ± 15% | |
| basal cell | 6 studies | 26% ± 11% | |
| Mueller cell | 6 studies | 75% ± 21% | |
| endothelial cell | 5 studies | 31% ± 12% | |
| interneuron | 5 studies | 44% ± 24% | |
| retinal ganglion cell | 4 studies | 60% ± 23% | |
| amacrine cell | 4 studies | 36% ± 14% | |
| cardiac muscle cell | 4 studies | 24% ± 3% | |
| brush cell | 4 studies | 35% ± 22% | |
| glial cell | 4 studies | 33% ± 13% | |
| GABAergic interneuron | 3 studies | 25% ± 8% | |
| GABAergic amacrine cell | 3 studies | 48% ± 8% | |
| neural progenitor cell | 3 studies | 31% ± 12% | |
| ependymal cell | 3 studies | 35% ± 17% | |
| granule cell | 3 studies | 36% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 99% | 33268.99 | 2617 / 2642 | 100% | 93.28 | 705 / 705 |
| lung | 100% | 19723.39 | 576 / 578 | 92% | 26.89 | 1066 / 1155 |
| prostate | 95% | 10487.53 | 232 / 245 | 90% | 21.59 | 452 / 502 |
| intestine | 59% | 5432.31 | 574 / 966 | 86% | 16.87 | 452 / 527 |
| esophagus | 53% | 4131.38 | 767 / 1445 | 89% | 22.00 | 162 / 183 |
| adrenal gland | 63% | 5283.16 | 163 / 258 | 77% | 159.29 | 177 / 230 |
| breast | 47% | 3519.03 | 217 / 459 | 83% | 17.81 | 924 / 1118 |
| bladder | 52% | 4906.52 | 11 / 21 | 73% | 14.18 | 370 / 504 |
| stomach | 36% | 2990.91 | 129 / 359 | 88% | 18.99 | 253 / 286 |
| uterus | 55% | 4613.04 | 93 / 170 | 60% | 12.15 | 276 / 459 |
| ovary | 61% | 5105.97 | 110 / 180 | 53% | 7.29 | 226 / 430 |
| ureter | 0% | 0 | 0 / 0 | 100% | 6.15 | 1 / 1 |
| blood vessel | 99% | 42788.47 | 1326 / 1335 | 0% | 0 | 0 / 0 |
| thymus | 23% | 1463.98 | 152 / 653 | 74% | 10.64 | 445 / 605 |
| pancreas | 1% | 56.01 | 4 / 328 | 96% | 35.57 | 170 / 178 |
| skin | 57% | 4065.98 | 1032 / 1809 | 38% | 12.36 | 177 / 472 |
| heart | 94% | 72944.76 | 807 / 861 | 0% | 0 | 0 / 0 |
| kidney | 25% | 1929.97 | 22 / 89 | 68% | 18.34 | 614 / 901 |
| tonsil | 0% | 0 | 0 / 0 | 76% | 15.24 | 34 / 45 |
| spleen | 38% | 2555.71 | 91 / 241 | 0% | 0 | 0 / 0 |
| liver | 0% | 0 | 0 / 226 | 31% | 6.81 | 125 / 406 |
| adipose | 31% | 2479.42 | 369 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 19% | 7.18 | 15 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 10% | 0.77 | 3 / 29 |
| muscle | 1% | 75.54 | 11 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0032348 | Biological process | negative regulation of aldosterone biosynthetic process |
| GO_0017015 | Biological process | regulation of transforming growth factor beta receptor signaling pathway |
| GO_0016055 | Biological process | Wnt signaling pathway |
| GO_2000065 | Biological process | negative regulation of cortisol biosynthetic process |
| GO_0030325 | Biological process | adrenal gland development |
| GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
| GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
| GO_1902613 | Biological process | negative regulation of anti-Mullerian hormone signaling pathway |
| GO_0009653 | Biological process | anatomical structure morphogenesis |
| GO_0005615 | Cellular component | extracellular space |
| GO_0048019 | Molecular function | receptor antagonist activity |
| GO_0039706 | Molecular function | co-receptor binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | DKK3 |
| Protein name | Putative tumor suppressor Dkk-3/REIC Dickkopf-related protein 3 (Dickkopf-3) (Dkk-3) (hDkk-3) Dickkopf WNT signaling pathway inhibitor 3 |
| Synonyms | REIC UNQ258/PRO295 |
| Description | FUNCTION: Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6. DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease (By similarity). . |
| Accessions | ENST00000326932.8 E9PKW6 Q6PQ81 ENST00000396505.7 ENST00000683431.1 Q9UBP4 ENST00000529338.1 ENST00000534511.5 ENST00000533813.5 F6SYF8 E9PKK9 ENST00000525493.5 E9PHY3 |